Call for Speaker Proposals
第3屆
Cancer Biologics
-抗癌生物製劑學會-
複合體、多特異性、生物標誌及最新的方法
2月21日∼23日
迎接第3年的此學會，成為能在癌治療藥創藥的重要領域學習的寶貴機會，採用強有力的標的設定功能和實現效應功能（effector function）的最新工學方法進行臨床前開發與轉譯（translational）研究、以及臨床的進展等主題。此外，亦聚焦於抗體藥物複合體、多特異性產品、併用療法、免疫療法、疫苗等，檢討因應核酸生物製劑和癌幹細胞標的化新領域的最新方法、克服傳遞和腫瘤滲透課題的手段等。
Who should attend: VPs, Directors, CEOs, CSOs and Scientists from Large Pharma, Biotechs and Academia in such fields as R&D, Product Development, Translational Medicine, Protein Engineering, Target Discovery
Topics will include, but are not limited to advances in the following:
- Advances with antibody-drug conjugates
- Bi- and multi-specific biotherapeutics
- Combination therapies
- Nucleic acid therapies (RNAi and siRNA)
- Immunotherapies, vaccines and adoptive T cell therapy
- Targeting cancer stem cells
- Identification of novel targets
- Novel engineering and platforms
- Penetration and delivery to solid tumors
- Translational and clinical biomarkers
- Pre-clinical and clinical advances
- Strategies for regulatory approval, licensing and success in the market
The deadline for submission is July 29, 2011.
All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program. Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
